TIDMAVCT
RNS Number : 2159O
Avacta Group PLC
29 September 2023
29 September 2023
Avacta Group plc
("Avacta", the "Group" or the "Company")
Director/PDMR Shareholdings
Avacta Group plc (AIM: AVCT), a life sciences company focused on
improving healthcare outcomes through targeted cancer treatments
and diagnostics, announces it has granted a total of 2,500,000
options over ordinary shares of 10p each ("Ordinary Shares") to
certain directors of the Company (the "Options").
These Options were granted under the Company's Long term
Incentive Plan, Avacta Group plc Executive Share Option Scheme as
set out below:
Director Position Number of Options Exercise
Granted Price
Alastair Smith CEO 1,250,000 10p
---------- ------------------ ---------
Tony Gardiner CFO 1,250,000 10p
---------- ------------------ ---------
The vesting conditions are based on the share price performance
of the Company over the three year period up to 31 December 2025
relative to the performance of the FTSE AIM All Share Index during
the same period.
Following these awards, the total number of Options held by the
directors were as set out below:
Director Position Number of Options
held
Alastair Smith CEO 6,241,426
---------- ------------------
Tony Gardiner CFO 2,828,384
---------- ------------------
Dr Eliot Forster, Chairman of Avacta Group plc said:
"Following the completion of the 2020 LTIP award period and the
significant progress made within the Group during the year, I am
pleased to confirm that the Remuneration Committee has been able to
conclude the changes to the equity arrangements of Alastair and
Tony. These arrangements continue to align the interest of the
Executive Directors with the longer-term share price performance
interests of our shareholders."
-Ends-
For further information from Avacta Group plc, please
contact:
Avacta Group plc Tel: +44 (0) 1904 21 7070
Alastair Smith, Chief Executive www.avacta.com
Officer
Tony Gardiner, Chief Financial
Officer
Michael Vinegrad, Group Communications
Director
Stifel Nicolaus Europe Limited Tel: +44 (0) 207 710 7600
(Nomad and Joint Broker) www.stifel.com
Nicholas Moore / Nick Adams /
Samira Essebiyea / Nick Harland
/ William Palmer-Brown
Peel Hunt (Joint Broker)
James Steel / Chris Golden / Patrick www.peelhunt.com
Birkholm
ICR Consilium
Mary-Jane Elliott / Jessica Hodgson avacta@consilium-comms.com
/ Sukaina Virji
About Avacta Group plc - www.avacta.com
Avacta Group is a UK-based company focused on improving
healthcare outcomes through targeted cancer treatments and
diagnostics.
Avacta has two divisions: an oncology biotech division
harnessing proprietary therapeutic platforms to develop novel,
highly targeted cancer drugs, and a diagnostics division, which is
executing on an M&A led growth strategy to create a
full-spectrum diagnostics business focused on supporting healthcare
professionals and broadening access to testing. Avacta's two
proprietary platforms, Affimer(R) and pre|CISION(TM) underpin its
cancer therapeutics whilst the diagnostics division leverages the
Affimer(R) platform to drive competitive advantage in its
markets.
The pre|CISION(TM) platform modifies chemotherapy to be
activated only in the tumour tissue, reducing systemic exposure and
toxicity. This is achieved by harnessing an enzyme called FAP which
is highly upregulated in most solid tumours compared with healthy
tissues, turning chemotherapy into a "precision medicine". The lead
pre|CISION(TM) programme, AVA6000 a tumour activated form of
doxorubicin, is in Phase 1 studies and has shown dramatic
improvement in safety compared with standard doxorubicin, and early
signs of clinical activity.
Affimer(R) is a novel biologic platform which has significant
technical and commercial advantages compared with antibodies and is
used both to develop advanced immunotherapies and to improve the
performance of immunodiagnostics.
With a balanced business and capital allocation model: a
high-value oncology pipeline supported by a revenue generating,
fast-growing diagnostics business, Avacta seeks to create long-term
shareholder value alongside patient benefit.
To register for news alerts by email go to
www.avacta.com/investor-news-email-alerts
The information communicated in this announcement is inside
information for the purposes of Article 7 of Regulation
596/2014.
Notification and public disclosure of transactions by persons
discharging managerial responsibilities and persons closely
associated with them
1. Details of the person discharging managerial responsibilities
/ person closely associated
a) Name Alastair Smith
------------------------------- -----------------------------------------
2. Reason for the Notification
--------------------------------------------------------------------------
a) Position/status Chief Executive Officer
------------------------------- -----------------------------------------
b) Initial notification/Amendment Initial notification
------------------------------- -----------------------------------------
3. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
--------------------------------------------------------------------------
a) Name Avacta Group Plc
------------------------------- -----------------------------------------
b) LEI 2138009U3EG31OPMGH36
------------------------------- -----------------------------------------
4. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
--------------------------------------------------------------------------
a) Description of the Options over Ordinary
Financial instrument, Shares
type of instrument
Identification code GB00BYYW9G87
------------------------------- -----------------------------------------
b) Nature of the transaction Grant of Options over Ordinary Shares
------------------------------- -----------------------------------------
c) Price(s) and volume(s)
LTIP Exercise Price(s) Volume(s)
10.00 pence 1,250,000
----------
------------------------------- -----------------------------------------
d) Aggregated information: Grant of 1,250,000 options over Ordinary
* Aggregated volume Shares at an exercise price of 10p
* Price
------------------------------- -----------------------------------------
e) Date of the transaction 28 September 2023
------------------------------- -----------------------------------------
f) Place of the transaction Outside a trading venue
------------------------------- -----------------------------------------
1. Details of the person discharging managerial responsibilities
/ person closely associated
a) Name Tony Gardiner
------------------------------- -----------------------------------------
2. Reason for the Notification
--------------------------------------------------------------------------
a) Position/status Chief Financial Officer
------------------------------- -----------------------------------------
b) Initial notification/Amendment Initial notification
------------------------------- -----------------------------------------
3. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
--------------------------------------------------------------------------
a) Name Avacta Group Plc
------------------------------- -----------------------------------------
b) LEI 2138009U3EG31OPMGH36
------------------------------- -----------------------------------------
4. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
--------------------------------------------------------------------------
a) Description of the Options over Ordinary
Financial instrument, Shares
type of instrument
Identification code GB00BYYW9G87
------------------------------- -----------------------------------------
b) Nature of the transaction Grant of Options over Ordinary Shares
------------------------------- -----------------------------------------
c) Price(s) and volume(s)
LTIP Exercise Price(s) Volume(s)
10.0 pence 1,250,000
----------
------------------------------- -----------------------------------------
d) Aggregated information: Grant of 1,250,000 options over Ordinary
* Aggregated volume Shares at an exercise price of 10p
* Price
------------------------------- -----------------------------------------
e) Date of the transaction 28 September 2023
------------------------------- -----------------------------------------
f) Place of the transaction Outside a trading venue
------------------------------- -----------------------------------------
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
DSHNKCBBBBKDKCB
(END) Dow Jones Newswires
September 29, 2023 08:30 ET (12:30 GMT)
Grafico Azioni Avacta (LSE:AVCT)
Storico
Da Apr 2024 a Mag 2024
Grafico Azioni Avacta (LSE:AVCT)
Storico
Da Mag 2023 a Mag 2024
